PATENT CLAIM ANALYSIS

Application Number: 16020688
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "267000"]

Abstract:
The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are methods and kits for treating cancer and solid tumors in a subject, as well as methods and kits for inducing cancer cell death and apoptosis of a cancer cell, all utilizing the NF-κB inhibitors described herein.

Claim (Index 55):
The method according to  claim 24 , wherein the cancer is selected from the group consisting of esophageal cancer, stomach cancer, small intestinal cancer, colon cancer, rectal cancer, anal cancer, liver cancer, intrahepatic bile duct cancer, gallbladder cancer, pancreatic cancer, larynx cancer, lung cancer, bronchus cancer, bone cancer, skin cancer, melanoma, breast cancer, uterine cervix cancer, uterine corpus cancer, ovarian cancer, vulva cancer, vaginal cancer, prostate cancer, testis cancer, urinary bladder cancer, kidney cancer, brain cancer, nervous system cancer, thyroid cancer, and thymus cancer.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.59091
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15393507', '12604970', '14032739', '13035640', '14088804']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8147411227972778
- 35 USC 102 Novelty (BERT): 0.557776043524071
- Combined Prediction Score: 0.7890446148699571
- Mean Citation Score: 335.78576400000014
- Max Citation Score: 451.7303
- Similarity Product: 337.1698259529829

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test